GenSight Biologics (Lumevoq)

GenSight Biologics (Lumevoq)

A Paris biopharma leader in gene therapy, utilizing AI in Feb 2026.nnKey FeaturesnUses optogenetics and mitochondrial targeting to treat rare blinding diseases, with production optimized by AI-driven tech transfers.nnUse CasenCurrently in Phase III trials (RECOVER), using AI to analyze patient response data for treating Leber Hereditary Optic Neuropathy.nnWhy Choose GenSight?nIt represents the cutting edge of ‘French Biotech,’ combining AI-driven clinical research with revolutionary gene-editing technology.

Outils connexes

The sovereign AI compliance tool for automated labeling and detection of AI-generated content. …
The AI agent platform for automating clinical documentation and hospital administrative tasks. …
The energy-efficient photonic AI processor using light to solve the AI compute crisis. …

Obtenez cet outil d'IA maintenant